Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 0 0 1 1 0
3557 3557 3557 3 35 355 3557 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
-Cell Therapy -cell - -C -Ce -Cel BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 - 1 10 0 0 0 0 0
ARTICLE ARTICLE article A AR ART ARTI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 2 0 0 0 0 0
Management of management M Ma Man Mana BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
receptor T-cell receptor r re rec rece BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -: 2 10 0 1 0 0 1
Blood and blood B Bl Blo Bloo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 5 0 1 0 0 1
Olaf Penack, olaf O Ol Ola Olaf BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 ,,,,,,,,,, 10 10 0 1 0 0 1
Hélène Schoemans, hélène H Hé Hél Hélè BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ,,,,,, 6 10 1 1 0 0 1
1 1 1 1 1 1 1 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 1 no 0 10 1 1 0 0 1
Medical Clinic, medical M Me Med Medi BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 ,,, 3 10 1 1 0 0 1
Universitätsmedizin Berlin, universitätsmedizin U Un Uni Univ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 ,,;, 4 10 1 1 0 0 1
Department of department D De Dep Depa BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 ,,-,, 5 10 1 1 0 0 1
Paris, France; paris, P Pa Par Pari BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 ,;,,, 5 10 1 0 0 0 1
INSERM UMR-S inserm I IN INS INSE BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 -,,,;, 6 10 1 0 0 0 1
University Hospital university U Un Uni Univ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 ,,; 3 10 1 0 0 0 1
St Petersburg, st S St St St BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 2 ,,;, 4 10 1 0 0 0 1
and KU and a an and and BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,,;,, 5 10 1 0 0 0 1
Hannover, Germany; hannover, H Ha Han Hann BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 3 ,;,',, 6 10 1 0 0 0 1
9 9 9 9 9 9 9 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 3 no 0 10 1 0 0 0 1
Department of department D De Dep Depa BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 ,,, 3 10 1 0 0 0 1
Abstract Abstract abstract A Ab Abs Abst BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 10 0 0 0 0 1
Chimeric antigen chimeric C Ch Chi Chim BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 3 (), 3 10 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 -,. 3 8 0 0 0 0 1
field of field f fi fie fiel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 3 -,- 3 9 0 0 0 0 1
es between es e es es es BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 ,--. 4 9 0 0 0 0 1
the current the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 -() 3 9 0 0 0 0 1
determine the determine d de det dete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 no 0 9 0 0 0 0 1
Party performed party P Pa Par Part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 3 -.() 4 9 0 0 0 0 1
addressing questions addressing a ad add addr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,-, 3 9 0 0 0 0 1
immune effector immune i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 -- 2 9 0 0 0 0 1
penias. We penias. p pe pen peni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 3 ., 2 9 0 0 0 0 1
the centers the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 . 1 9 0 0 0 0 1
clinical research clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 :-/- 4 9 0 0 0 0 1
toxicity, treatment toxicity, t to tox toxi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 3 ,,,. 4 9 0 0 0 0 1
Introduction Introduction introduction I In Int Intr BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 10 0 1 0 0 1
Chimeric antigen chimeric C Ch Chi Chim BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 7 ()- 3 8 0 1 0 0 1
clinical routine clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 .(- 3 9 0 1 0 0 1
phomas, leukemias) phomas, p ph pho phom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 ,)-( 4 8 0 1 0 0 1
myeloma) have myeloma) m my mye myel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 ) 1 8 0 1 0 0 1
relapsed or relapsed r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 .-,, 4 10 0 1 0 0 1
shows the shows s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 8 0 1 0 0 1
respective indications. respective r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 . 1 8 0 1 0 0 1
different antigen different d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 9 0 1 0 0 1
the near the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 , 1 8 0 1 0 0 1
studies that studies s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 . 1 8 0 1 0 0 1
CAR T car C CA CAR CAR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 8 0 1 0 0 1
treatment. However, treatment. t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 .,-- 4 8 0 1 0 0 1
be substantial. be b be be be BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 .,- 3 9 0 1 0 0 1
going CAR going g go goi goin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 - 1 9 0 1 0 0 1
care, which care, c ca car care BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 , 1 9 0 1 0 0 1
T-cell centers. t-cell T T- T-c T-ce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 -. 2 9 0 1 0 0 1
on expert on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 .- 2 9 0 1 0 0 1
fore hypothesized fore f fo for fore BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 no 0 9 0 1 0 0 1
differences in differences d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 ,, 2 9 0 1 0 0 1
patients undergoing patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 -.- 3 9 0 1 0 0 1
mine the mine m mi min mine BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 no 0 10 0 1 0 0 1
research, we research, r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 , 1 9 0 1 0 0 1
of short-and of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 - 1 9 0 1 0 0 1
T-cell therapy t-cell T T- T-c T-ce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 -. 2 4 0 1 0 0 1
Our main our O Ou Our Our BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 :)- 3 9 0 1 0 0 1
cal setting cal c ca cal cal BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 1 9 ,)-- 4 9 0 1 0 0 1
Correspondence: O. correspondence: C Co Cor Corr BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 :. 2 10 1 1 0 0 1
olaf.penack@charite.de olaf.penack@charite.de olaf.penack@charite.de o ol ola olaf BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 1 0 1 11 .@. 3 10 1 1 0 0 1
Received: Received: received: R Re Rec Rece BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 : 1 5 1 1 0 0 1
December 5, december D De Dec Dece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 1 0 0 1 11 ,. 2 10 1 1 0 0 1
Accepted: Accepted: accepted: A Ac Acc Acce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 : 1 5 1 1 0 0 1
May 21, may M Ma May May BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 1 0 0 1 11 ,. 2 7 1 1 0 0 1
Early view: early E Ea Ear Earl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 11 : 1 6 1 1 0 0 1
May 30, may M Ma May May BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 1 0 0 1 11 ,. 2 7 1 1 0 0 1
https://doi.org/10.3324/haematol.2023.284810 https://doi.org/10.3324/haematol.2023.284810 https://doi.org/10.3324/haematol.2023.284810 h ht htt http BLOCKSTART PAGEIN SAMEFONT LOWERFONT 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 1 11 ://././.. 9 10 1 0 0 0 1
©2024 Ferrata ©2024 © ©2 ©20 ©202 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 1 11 no 0 10 1 0 0 0 1
Published under published P Pu Pub Publ BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 - 1 10 1 0 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 10 0 0 1 0 0
3558 3558 3558 3 35 355 3558 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 1 0 no 0 10 0 0 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 10 0 1 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 .. 2 6 0 1 0 0 0
roid-refractory cases roid-refractory r ro roi roid BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 -() 3 9 0 1 0 0 1
are managed, are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,) 2 9 0 1 0 0 1
drugs are drugs d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 1 0 0 1
neurotoxicity syndrome neurotoxicity n ne neu neur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (),) 4 9 0 1 0 0 1
CAR T-cell car C CA CAR CAR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 1 0 0 1
hematopoietic stem hematopoietic h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ) 1 10 0 1 0 0 1
where and where w wh whe wher BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 0 1 0 0 1
therapy is therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 9 0 1 0 0 1
areas where areas a ar are area BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 1 0 0 1
their high their t th the thei BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 7 0 1 0 0 1
Methods Methods methods M Me Met Meth BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 10 0 0 0 0 1
The European the T Th The The BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 9 0 0 0 0 1
(EBMT) is (ebmt) ( (E (EB (EBM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 1 () 2 9 0 0 0 0 1
that are that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -- 2 9 0 0 0 0 1
utive stem utive u ut uti utiv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 ., 2 9 0 0 0 0 1
started to started s st sta star BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -, 2 10 0 0 0 0 1
design and design d de des desi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 (). 3 9 0 0 0 0 1
In the in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 1 - 1 9 0 0 0 0 1
of commercial of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 9 0 0 0 0 1
and data and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 9 0 0 0 0 1
intervals of intervals i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ,. 2 9 0 0 0 0 1
routinely performed routinely r ro rou rout BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 . 1 9 0 0 0 0 1
The study the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 9 0 0 0 0 1
plications Working plications p pl pli plic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 . 1 9 0 0 0 0 1
We designed we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 8 0 0 0 0 1
discussed/edited them discussed/edited d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 /-. 3 8 0 0 0 0 1
questions and questions q qu que ques BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 8 0 0 0 0 1
vided in vided v vi vid vide BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 . 1 9 0 0 0 0 1
close-ended. However, close-ended. c cl clo clos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -., 3 8 0 0 0 0 1
opportunity to opportunity o op opp oppo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 , 1 9 0 0 0 0 1
provide reasoning provide p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 , 1 9 0 0 0 0 1
answer. The answer. a an ans answ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 . 1 8 0 0 0 0 1
then designed then t th the then BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 8 0 0 0 0 1
the PI the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 -. 2 8 0 0 0 0 1
launched on launched l la lau laun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ,, 2 9 0 0 0 0 1
2023. All 2023. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 1 1 .- 2 8 0 0 0 0 1
time period. time t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 . 1 9 0 0 0 0 1
collected through collected c co col coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 - 1 8 0 0 0 0 1
line survey line l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 .' 2 9 0 0 0 0 1
Therapy Form therapy T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 .- 2 8 0 0 0 0 1
alyzed using alyzed a al aly alyz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 . 1 9 0 0 0 0 1
were summarized were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ,() 3 8 0 0 0 0 1
and range and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 (). 3 8 0 0 0 0 1
were presented were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 . 1 7 0 0 0 0 1
The survey the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 no 0 8 0 0 0 0 1
CAR T-cell car C CA CAR CAR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 1 -.: 3 8 0 0 0 0 1
i) Tisagenlecleucel i) i i) i) i) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 )(-,,) 6 9 0 0 0 0 1
of acute of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ,--- 4 9 0 0 0 0 1
(diffuse LBL) (diffuse ( (d (di (dif BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 (). 3 7 0 0 0 0 1
ii) Axicabtagene ii) i ii ii) ii) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 1 )(-,/,) 7 9 0 0 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 ,-, 3 8 0 0 0 0 1
primary mediastinal primary p pr pri prim BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 1 . 1 7 0 0 0 0 1
iii) Lisocabtagene iii) i ii iii iii) BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 )(-,,) 6 9 0 1 0 0 1
treatment of treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 ,- 2 9 0 1 0 0 1
lymphoma and lymphoma l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 . 1 5 0 1 0 0 1
iv) Brexucabtagene iv) i iv iv) iv) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 )(-,/,) 7 10 0 1 0 0 1
for treatment for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 , 1 9 0 1 0 0 1
LBCL and lbcl L LB LBC LBCL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 . 1 5 0 1 0 0 1
v) Idecabtagene v) v v) v) v) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 )(-,,)- 7 9 0 1 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 . 1 4 0 1 0 0 1
vi) Ciltacabtagene vi) v vi vi) vi) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 )(-,,) 6 9 0 1 0 0 1
for treatment for f fo for for BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 . 1 5 0 1 0 0 1
Results Results results R Re Res Resu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 7 no 0 10 0 0 0 0 1
One hundred one O On One One BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 8 0 0 0 0 1
online survey. online o on onl onli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 .- 2 9 0 0 0 0 1
egories: product egories: e eg ego egor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 :(),- 5 10 0 0 0 0 1
(Figure 2), (figure ( (F (Fi (Fig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 (),(), 6 9 0 0 0 0 1
ICANS (Figure icans I IC ICA ICAN BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 7 () 2 9 0 0 0 0 1
prolonged cytopenias prolonged p pr pro prol BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 (). 3 5 0 0 0 0 1
Product selection product P Pr Pro Prod BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 () 2 4 0 0 0 0 1
Most centers most M Mo Mos Most BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 () 2 9 0 0 0 0 1
CAR T-cell car C CA CAR CAR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 -. 2 9 0 0 0 0 1
1. The 1. 1 1. 1. 1. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 . 1 9 0 0 0 0 1
licensed CAR licensed l li lic lice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -. 2 8 0 0 0 0 1
targeting CAR targeting t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -, 2 9 0 0 0 0 1
of centers of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 :(-), 5 9 0 0 0 0 1
(Axi-Cel) 84%, (axi-cel) ( (A (Ax (Axi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 (-),(-)(- 9 9 0 0 0 0 1
so-Cel) 24%. so-cel) s so so- so-C BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 -). 3 9 0 0 0 0 1
for use for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 8 0 0 0 0 1
myeloma was myeloma m my mye myel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 (-) 3 8 0 0 0 0 1
18% for 18% 1 18 18% 18% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 (-). 4 4 0 0 0 0 1
Currently, three currently, C Cu Cur Curr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 , 1 9 0 0 0 0 1
(Kymriah, Yescarta (kymriah, ( (K (Ky (Kym BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 (,). 4 9 0 0 0 0 1
centers decide centers c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
for preferences. for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 .() 3 9 0 0 0 0 1
they are they t th the they BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 8 0 0 0 0 1
or Breyanzi; or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ; 1 9 0 0 0 0 1
use the use u us use use BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 . 1 9 0 0 0 0 1
share of share s sh sha shar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 (), 3 8 0 0 0 0 1
more often more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 () 2 9 0 0 0 0 1
more often more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 (). 3 9 0 0 0 0 1
The primary the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
higher effectiveness higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 (). 3 10 0 0 0 0 1
selection were selection s se sel sele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
(41%), a (41%), ( (4 (41 (41% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 7 (),()- 6 10 0 0 0 0 1
preservation (28%). preservation p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 (). 3 9 0 0 0 0 1
for production for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ,- 2 9 0 0 0 0 1
pheresis products. pheresis p ph phe pher BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 . 1 9 0 0 0 0 1
earlier apheresis, earlier e ea ear earl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 , 1 9 0 0 0 0 1
for immediate for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 . 1 5 0 0 0 0 1
In multiple in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 7 ,-- 3 8 0 0 0 0 1
tigen (BCMA) tigen t ti tig tige BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 () 2 8 0 0 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 10 1 0 1 0 0
3559 3559 3559 3 35 355 3559 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 0 no 0 10 1 0 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 3 0 - 1 10 0 0 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 .. 2 6 0 0 0 0 0
(Abecma and (abecma ( (A (Ab (Abe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ()- 3 8 1 1 0 0 1
tified for tified t ti tif tifi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 . 1 10 1 1 0 0 1
LBCL, we lbcl, L LB LBC LBCL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 9 1 1 0 0 1
projects they projects p pr pro proj BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 0 : 1 9 1 1 0 0 1
using exclusively using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ; 1 9 1 1 0 0 1
use more use u us use use BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 1 1 0 0 1
the other the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 , 1 9 1 1 0 0 1
sometimes Abecma. sometimes s so som some BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ., 2 8 1 1 0 0 1
both products both b bo bot both BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 . 1 9 1 1 0 0 1
the situation the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 ,- 2 10 1 1 0 0 1
product selection product p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 no 0 9 1 1 0 0 1
availability of availability a av ava avai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 ().' 4 9 1 1 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 ' 1 9 1 1 0 0 1
primary reason primary p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 , 1 9 1 1 0 0 1
the recent/current the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 3 / 1 9 1 1 0 0 1
BCMA targeting bcma B BC BCM BCMA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 . 1 5 1 1 0 0 1
Figure 2. figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 .-.()- 6 9 1 0 0 0 1
matic diagram matic m ma mat mati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ()-.(). 7 9 1 0 0 0 1
(C) Clinical (c) ( (C (C) (C) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 6 ()-,()- 7 10 1 0 0 0 1
without serious without w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ... 3 4 1 0 0 0 1
A A a A A A A BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 1 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 3 9 no 0 10 1 1 0 0 1
B B b B B B B BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
C C c C C C C BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
D D d D D D D BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 9 no 0 10 0 0 0 0 1
Figure 1. figure F Fi Fig Figu BLOCKSTART PAGEIN SAMEFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 9 .-- 3 9 1 1 0 0 1
agement of agement a ag age agem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 9 .- 2 10 1 1 0 0 1
tor (CAR) tor t to tor tor BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 9 ()-...:. 8 9 1 1 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 1 1 0 0
3560 3560 3560 3 35 356 3560 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 1 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 10 0 0 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 .. 2 6 0 0 0 0 0
CAR T-cell car C CA CAR CAR BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 -() 3 5 1 1 0 0 1
We were we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 1 1 0 0 1
place, before, place, p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,,-. 4 9 1 1 0 0 1
Roughly 60% roughly R Ro Rou Roug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 -- 2 9 1 1 0 0 1
depletion, as depletion, d de dep depl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,, 2 10 1 1 0 0 1
wards (as wards w wa war ward BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ().- 4 9 1 1 0 0 1
ingly, 8% ingly, i in ing ingl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ,- 2 9 1 1 0 0 1
formed in formed f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ; 1 9 1 1 0 0 1
that CAR that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 9 1 1 0 0 1
care ward care c ca car care BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 1 1 0 0 1
patient-related factors patient-related p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -- 2 9 1 1 0 0 1
sus normal sus s su sus sus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ., 2 9 1 1 0 0 1
relevant role relevant r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 1 1 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 0 . 1 5 1 1 0 0 1
The majority the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 () 2 9 1 1 0 0 1
severe complications severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 1 1 0 0 1
day +14 day d da day day BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 0 ; 1 9 1 1 0 0 1
later after later l la lat late BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ., 2 9 1 1 0 0 1
few centers few f fe few few BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 8 0 0 0 0 1
(2%). However, (2%). ( (2 (2% (2%) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 ().,() 6 10 0 0 0 0 1
patients relatively patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
CAR T car C CA CAR CAR BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 . 1 2 0 0 0 0 1
Cytokine release cytokine C Cy Cyt Cyto BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 () 2 7 1 1 0 0 1
We were we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 8 1 1 0 0 1
of CRS of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 - 1 9 1 1 0 0 1
ability of ability a ab abi abil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 . 1 10 1 1 0 0 1
by far by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 9 1 1 0 0 1
first-line treatment first-line f fi fir firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 -,- 3 9 1 1 0 0 1
ond-line treatment ond-line o on ond ond- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 7 -., 3 9 1 1 0 0 1
of comorbidities, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 , 1 9 1 1 0 0 1
CRS and crs C CR CRS CRS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 no 0 9 1 1 0 0 1
named as named n na nam name BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 9 1 1 0 0 1
start first-and start s st sta star BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 --. 3 7 1 1 0 0 1
We also we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 8 1 1 0 0 1
cases. The cases. c ca cas case BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 .() 3 9 1 1 0 0 1
Figure 3. figure F Fi Fig Figu BLOCKSTART PAGEIN SAMEFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 . 1 10 1 1 0 0 1
release syndrome. release r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 11 .:;-:- 6 10 1 1 0 0 1
leukin 6; leukin l le leu leuk BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 11 ;:. 3 6 1 1 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 1 1 0 0
3561 3561 3561 3 35 356 3561 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 1 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 10 0 0 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 .. 2 6 0 0 0 0 0
are always are a ar are are BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 8 1 1 0 0 1
istering a istering i is ist iste BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 (). 3 9 1 1 0 0 1
Only 19% only O On Onl Only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 1 1 0 0 1
with steroids, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,. 2 6 1 1 0 0 1
Anakinra is anakinra A An Ana Anak BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 10 1 1 0 0 1
of centers of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ().,: 5 9 1 1 0 0 1
of centers of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -/, 3 8 1 1 0 0 1
for rheumatoid for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ;-, 3 8 1 1 0 0 1
anakinra/day, which anakinra/day, a an ana anak BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 /, 2 9 1 1 0 0 1
severe inflammatory severe s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,- 2 9 1 1 0 0 1
periodic syndrome periodic p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ().- 4 10 1 1 0 0 1
preferred by preferred p pr pre pref BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 (-) 3 10 1 1 0 0 1
antibody (12%) antibody a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 ()()., 6 8 1 1 0 0 1
of centers of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 1 1 0 0 1
strategies in strategies s st str stra BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 8 1 1 0 0 1
Immune effector immune I Im Imm Immu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 - 1 8 1 1 0 0 1
management (Figure management m ma man mana BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 6 () 2 3 1 1 0 0 1
We first we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 - 1 10 1 1 0 0 1
suspected or suspected s su sus susp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 : 1 9 1 1 0 0 1
magnetic resonance magnetic m ma mag magn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 (),- 4 9 1 1 0 0 1
encephalography and encephalography e en enc ence BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 6 no 0 9 1 1 0 0 1
fluid puncture fluid f fl flu flui BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 . 1 10 1 1 0 0 1
the management the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 , 1 9 1 1 0 0 1
is the is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 no 0 9 1 1 0 0 1
used or used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 .- 2 10 1 1 0 0 1
ment decisions ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 6 , 1 9 1 1 0 0 1
from CAR from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 - 1 9 1 1 0 0 1
of CAR-T of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 -. 2 5 1 1 0 0 1
The majority the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 ()- 3 9 1 1 0 0 1
ways waiting ways w wa way ways BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 no 0 10 1 1 0 0 1
Figure 4. figure F Fi Fig Figu BLOCKSTART PAGEIN SAMEFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 .-.:- 5 9 1 1 0 0 1
tor cell-associated tor t to tor tor BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 -;:;:;-:. 9 10 1 1 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 10 0 1 1 0 0
3562 3562 3562 3 35 356 3562 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 0 no 0 10 0 1 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 10 0 0 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 .. 2 6 0 0 0 0 0
a third a a a a a BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 0 (). 3 9 0 0 0 0 1
25% of 25% 2 25 25% 25% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
with steroids, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,. 2 10 0 0 0 0 1
drug of drug d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
in most in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 (). 3 8 0 0 0 0 1
with anakinra, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,.- 3 9 0 0 0 0 1
tive option tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
alternative IL-6 alternative a al alt alte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -., 3 10 0 0 0 0 1
answered that answered a an ans answ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 / 1 9 0 0 0 0 1
on top on o on on on BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 6 0 0 0 0 1
Management in management M Ma Man Mana BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 1 no 0 7 0 1 0 0 1
prolonged cytopenias prolonged p pr pro prol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 () 2 4 0 1 0 0 1
Deficiency of deficiency D De Def Defi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 () 2 8 0 1 0 0 1
patients treated patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 --. 3 9 0 1 0 0 1
We were we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 9 0 1 0 0 1
IgG and igg I Ig IgG IgG BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 9 0 1 0 0 1
Agency (EMA) agency A Ag Age Agen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 (). 3 9 0 1 0 0 1
a significant a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 1 no 0 9 0 1 0 0 1
asymptomatic patients asymptomatic a as asy asym BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 ([/ 3 8 0 1 0 0 1
and <IgG and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 /]). 4 10 0 1 0 0 1
centers (40%) centers c ce cen cent BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 3 () 2 10 0 1 0 0 1
infections are infections i in inf infe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 9 0 1 0 0 1
following the following f fo fol foll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 . 1 9 0 1 0 0 1
routinely substitute routinely r ro rou rout BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 -. 2 10 0 1 0 0 1
In patients in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 3 -( 2 9 0 1 0 0 1
collected CD34 collected c co col coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ),- 3 9 0 1 0 0 1
ters consider ters t te ter ters BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 - 1 9 0 1 0 0 1
for prolonged for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ; 1 9 0 1 0 0 1
back-ups in back-ups b ba bac back BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 -- 2 8 0 1 0 0 1
prolonged cytopenia. prolonged p pr pro prol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 ., 2 8 0 1 0 0 1
the ideal the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 - 1 9 0 1 0 0 1
uation. A uation. u ua uat uati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 . 1 9 0 1 0 0 1
but some but b bu but but BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 9 0 1 0 0 1
between day between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 -. 2 8 0 1 0 0 1
Eighty percent eighty E Ei Eig Eigh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 - 1 9 0 1 0 0 1
ony-stimulating factor ony-stimulating o on ony ony- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 -(-) 4 9 0 1 0 0 1
after CAR after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 -, 2 9 0 1 0 0 1
regarding severity regarding r re reg rega BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 -. 2 9 0 1 0 0 1
Fifty percent fifty F Fi Fif Fift BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 8 0 1 0 0 1
cutoff at cutoff c cu cut cuto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 / 1 9 0 1 0 0 1
use different use u us use use BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 //. 3 9 0 1 0 0 1
Table 1. table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 .. 2 10 0 1 0 0 1
Questions and questions Q Qu Que Ques BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 10 0 1 0 0 1
Percentage of percentage P Pe Per Perc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 4 0 1 0 0 1
answers selected answers a an ans answ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 6 no 0 5 0 1 0 0 1
Which statements which W Wh Whi Whic BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 6 ? 1 7 0 0 0 0 1
I substitute i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 / 1 6 0 0 0 0 1
I substitute i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 / 1 6 0 0 0 0 1
I substitute i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 no 0 10 0 0 0 0 1
I never i I I I I BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 6 no 0 3 0 0 0 0 1
46 46 46 4 46 46 46 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
11 11 11 1 11 11 11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
40 40 40 4 40 40 40 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
3 3 3 3 3 3 3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 7 no 0 6 0 0 0 0 1
Do you do D Do Do Do BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 -( 2 10 0 0 0 0 1
a previous a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 6 7 )? 2 2 0 0 0 0 1
Never Never never N Ne Nev Neve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 0 0 0 0 0 1
Always Always always A Al Alw Alwa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 0 0 0 0 0 1
Yes, if yes, Y Ye Yes Yes, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 , 1 3 0 0 0 0 1
88 88 88 8 88 88 88 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
1 1 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 8 no 0 6 0 0 0 0 1
11 11 11 1 11 11 11 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
Which statements which W Wh Whi Whic BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
after CAR after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 ? 1 2 0 0 0 0 1
I do i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 8 no 0 7 0 0 0 0 1
First, waiting first, F Fi Fir Firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 ,,, 3 9 0 0 0 0 1
transplants after transplants t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 3 0 0 0 0 1
Giving autoSCT giving G Gi Giv Givi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 7 0 0 0 0 1
Early delivery early E Ea Ear Earl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 8 no 0 7 0 0 0 0 1
46 46 46 4 46 46 46 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
42 42 42 4 42 42 42 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
12 12 12 1 12 12 12 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
1 1 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 9 no 0 6 0 0 0 0 1
Which statements which W Wh Whi Whic BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
after CAR after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 ? 1 1 0 0 0 0 1
I do i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 no 0 4 0 0 0 0 1
I administer i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 / 1 5 0 0 0 0 1
I administer i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 / 1 5 0 0 0 0 1
I administer i I I I I BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 9 / 1 5 0 0 0 0 1
19 19 19 1 19 19 19 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
16 16 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
50 50 50 5 50 50 50 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
14 14 14 1 14 14 14 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 no 0 10 0 0 0 0 1
Which methods which W Wh Whi Whic BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 -? 2 10 0 1 0 0 1
I do i I I I I BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 6 10 - 1 4 0 1 0 0 1
Flow cytometry flow F Fl Flo Flow BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 no 0 1 0 1 0 0 1
PCR PCR pcr P PC PCR PCR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 no 0 0 0 1 0 0 1
Indirectly by indirectly I In Ind Indi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 - 1 3 0 1 0 0 1
23 23 23 2 23 23 23 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 no 0 10 0 1 0 0 1
59 59 59 5 59 59 59 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 no 0 10 0 1 0 0 1
11 11 11 1 11 11 11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 no 0 10 0 1 0 0 1
7 7 7 7 7 7 7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 11 no 0 6 0 1 0 0 1
IgG: immunoglobulin igg: I Ig IgG IgG: BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 :;:;:;:;:-- 11 10 0 1 0 0 1
lating factor; lating l la lat lati BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 11 ;:. 3 3 0 1 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 10 0 0 1 0 0
3563 3563 3563 3 35 356 3563 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 0 no 0 10 0 0 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 10 0 1 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 .. 2 6 0 1 0 0 0
Next, we next, N Ne Nex Next BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 ,- 2 8 0 1 0 0 1
persistence in persistence p pe per pers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 10 0 1 0 0 1
perform CAR perform p pe per perf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -. 2 8 0 1 0 0 1
methods are methods m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 0 1 0 0 1
chain reaction-based chain c ch cha chai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -. 2 4 0 1 0 0 1
Finally, we finally, F Fi Fin Fina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 ,- 2 9 0 1 0 0 1
ferences in ferences f fe fer fere BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 0 1 0 0 1
the country the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 . 1 9 0 1 0 0 1
re-analyzed our re-analyzed r re re- re-a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 - 1 9 0 1 0 0 1
focused on focused f fo foc focu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 - 1 9 0 1 0 0 1
ny, Italy ny, n ny ny, ny, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,. 2 9 0 1 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 (,,, 4 9 0 1 0 0 1
later phase) later l la lat late BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 )- 2 9 0 1 0 0 1
agement according agement a ag age agem BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 . 1 7 0 1 0 0 1
Discussion Discussion discussion D Di Dis Disc BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 10 0 0 0 0 1
In this in I In In In BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 1 -- 2 8 0 0 0 0 1
ters, we ters, t te ter ters BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 , 1 9 0 0 0 0 1
of complication of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 9 0 0 0 0 1
generally accepted generally g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
of extensive of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
trials leading trials t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 -. 2 9 0 0 0 0 1
more than more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 , 1 9 0 0 0 0 1
higher response higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ., 2 8 0 0 0 0 1
the other the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
raising the raising r ra rai rais BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
the European the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 -.,' 4 9 0 0 0 0 1
sure and sure s su sur sure BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 8 0 0 0 0 1
only state only o on onl only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 10 0 0 0 0 1
representative in representative r re rep repr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 (,, 3 9 0 0 0 0 1
Italy) are italy) I It Ita Ital BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 )- 2 9 0 0 0 0 1
are performed are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 9 0 0 0 0 1
have not have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 8 0 0 0 0 1
performed in performed p pe per perf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 - 1 9 0 0 0 0 1
dards or dards d da dar dard BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 . 1 6 0 0 0 0 1
Of note, of O Of Of Of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 ,. 2 9 0 0 0 0 1
addition a addition a ad add addi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
T-cell therapy t-cell T T- T-c T-ce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 - 1 9 0 0 0 0 1
trial investigations trial t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
products in products p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 8 0 0 0 0 1
can't comment can't c ca can can' BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ' 1 9 0 0 0 0 1
management may management m ma man mana BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 1 . 1 3 0 0 0 0 1
We found we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
T products t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 1 no 0 8 0 0 0 0 1
used for used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 ., 2 9 0 0 0 0 1
LBCL the lbcl L LB LBC LBCL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 1 no 0 9 0 0 0 0 1
efficacy. This efficacy. e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 . 1 9 0 0 0 0 1
high quality high h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 1 -,- 3 9 0 0 0 0 1
ical trials ical i ic ica ical BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 (- 2 9 0 0 0 0 1
mriah, Yescarta mriah, m mr mri mria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 1 ,) 2 8 0 0 0 0 1
efficacy. First efficacy. e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 .- 2 9 0 0 0 0 1
the outcome the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 8 0 0 0 0 1
products have products p pr pro prod BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 1 no 0 8 0 0 0 0 1
is currently is i is is is BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .,,, 4 9 0 1 0 0 1
survey was survey s su sur surv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 (), 3 8 0 1 0 0 1
production slot production p pr pro prod BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 no 0 8 0 1 0 0 1
was extremely was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 , 1 9 0 1 0 0 1
myeloma the myeloma m my mye myel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 no 0 8 0 1 0 0 1
was the was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 5 0 1 0 0 1
As expected, as A As As As BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 ,- 2 8 0 1 0 0 1
ment during ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 - 1 8 0 1 0 0 1
after CAR after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 8 0 1 0 0 1
health care health h he hea heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 . 1 9 0 1 0 0 1
requirements on requirements r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 8 0 1 0 0 1
future, it future, f fu fut futu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ,- 2 9 0 1 0 0 1
ulatory basis ulatory u ul ula ulat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 no 0 8 0 1 0 0 1
T treatment, t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 5 , 1 8 0 1 0 0 1
and other and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 3 0 1 0 0 1
Standard primary standard S St Sta Stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 8 0 1 0 0 1
homogeneous. 16 homogeneous. h ho hom homo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 8 0 1 0 0 1
homogenize the homogenize h ho hom homo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 - 1 9 0 1 0 0 1
very severe very v ve ver very BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 /. 2 9 0 1 0 0 1
shows that shows s sh sho show BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ,-, 3 9 0 1 0 0 1
used in used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
guidelines. However, guidelines. g gu gui guid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ., 2 9 0 1 0 0 1
needed to needed n ne nee need BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 8 0 1 0 0 1
inra in inra i in inr inra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
centers use centers c ce cen cent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 (-/) 4 9 0 1 0 0 1
to approved to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ., 2 10 0 1 0 0 1
approximetely one approximetely a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 , 1 9 0 1 0 0 1
probably as probably p pr pro prob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
for effective for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 /. 2 7 0 1 0 0 1
There is there T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
grading of grading g gr gra grad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 -- 2 9 0 1 0 0 1
the establishment the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 9 0 1 0 0 1
algorithms. 18-20 algorithms. a al alg algo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .-- 3 9 0 1 0 0 1
base that base b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 8 0 1 0 0 1
was 12.1% was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .-. 3 9 0 1 0 0 1
~50% of ~50% ~ ~5 ~50 ~50% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
+100, demonstrating +100, + +1 +10 +100 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 ,. 2 9 0 1 0 0 1
attractive opportunity attractive a at att attr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 9 0 1 0 0 1
the administration the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ( 1 9 0 1 0 0 1
blood stem blood b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ).,, 4 10 0 1 0 0 1
than 50% than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
boosts in boosts b bo boo boos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 9 0 1 0 0 1
timing of timing t ti tim timi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 , 1 8 0 1 0 0 1
demonstrated by demonstrated d de dem demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ., 2 9 0 1 0 0 1
we found we w we we we BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
hematopoietic stem hematopoietic h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 -, 2 9 0 1 0 0 1
probably reflecting probably p pr pro prob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 9 0 1 0 0 1
ment and ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 . 1 5 0 1 0 0 1
Patients after patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 9 0 1 0 0 1
therapies are therapies t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 8 0 1 0 0 1
and increased and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 .,, 3 9 0 1 0 0 1
generally accepted generally g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 0 1 0 0 1
our result our o ou our our BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 9 0 1 0 0 1
In summary, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 5 ,- 2 8 0 1 0 0 1
agement of agement a ag age agem BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 --. 3 8 0 1 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 1 0 0
3564 3564 3564 3 35 356 3564 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 10 0 0 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 .. 2 6 0 0 0 0 0
validation of validation v va val vali BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
in other in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 0 ,..,. 5 10 0 0 0 0 1
Our results our O Ou Our Our BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 10 0 0 0 0 1
evidence. A evidence. e ev evi evid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
concepts for concepts c co con conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 9 0 0 0 0 1
trials. Another trials. t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
clinical standards clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 10 0 0 0 0 1
world data world w wo wor worl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 9 0 0 0 0 1
zation. One zation. z za zat zati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ., 2 9 0 0 0 0 1
by the by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
(EHA). GoCART (eha). ( (E (EH (EHA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ().- 4 9 0 0 0 0 1
representatives, health representatives, r re rep repr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 9 0 0 0 0 1
companies, regulators, companies, c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 9 0 0 0 0 1
and reimbursement and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 8 0 0 0 0 1
collaborating to collaborating c co col coll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 10 0 0 0 0 1
Specific tasks specific S Sp Spe Spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ) 1 9 0 0 0 0 1
extensive and extensive e ex ext exte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 --- 3 9 0 0 0 0 1
plications in plications p pl pli plic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 -() 3 10 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 0 ,) 2 9 0 0 0 0 1
workshops by workshops w wo wor work BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ) 1 9 0 0 0 0 1
stand for stand s st sta stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
efforts by efforts e ef eff effo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -. 2 4 0 0 0 0 1
Disclosures Disclosures disclosures D Di Dis Disc BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 no 0 2 0 1 0 0 1
OP has op O OP OP OP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 9 2 , 1 9 0 1 0 0 1
Jazz, MSD, jazz, J Ja Jaz Jazz BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 2 ,,,. 4 10 0 1 0 0 1
research support research r re res rese BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 2 . 1 9 0 0 0 0 1
advisory boards advisory a ad adv advi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 ,,,,, 5 10 0 0 0 0 1
Omeros, Priothera, omeros, O Om Ome Omer BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 ,,,. 4 9 0 0 0 0 1
honoraria from honoraria h ho hon hono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 2 ,,,. 4 9 0 0 0 0 1
CK received ck C CK CK CK BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 ,, 2 9 0 0 0 0 1
Medigene, Janssen, medigene, M Me Med Medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 ,,,,,/ 6 8 0 0 0 0 1
Gilead and gilead G Gi Gil Gile BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 2 -. 2 9 0 0 0 0 1
conflicts of conflicts c co con conf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 2 . 1 5 0 0 0 0 1
Contributions Contributions contributions C Co Con Cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 2 0 0 0 0 1
OP designed op O OP OP OP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 9 3 ,- 2 9 0 0 0 0 1
script. WB, script. s sc scr scri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 .,,, 4 10 0 0 0 0 1
and edited and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 . 1 9 0 0 0 0 1
research and research r re res rese BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 . 1 6 0 0 0 0 1
Funding Funding funding F Fu Fun Fund BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 no 0 1 0 0 0 0 1
OP acknowledges op O OP OP OP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 9 4 - 1 8 0 0 0 0 1
kämie-Stiftung (3R/2019, kämie-stiftung k kä käm kämi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 -(/,/), 7 9 0 0 0 0 1
(70113519), Deutsche (70113519), ( (7 (70 (701 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 4 (),(/-, 7 10 0 0 0 0 1
PE 1450/9-1, pe P PE PE PE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 4 /-,/-)( 7 10 0 0 0 0 1
PRO_549, Focus pro_549, P PR PRO PRO_ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 4 ,). 3 7 0 0 0 0 1
Data-sharing statement data-sharing D Da Dat Data BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 - 1 3 0 1 0 0 1
The data the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 no 0 10 0 1 0 0 1
on request on o on on on BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 4 . 1 6 0 1 0 0 1
References References references R Re Ref Refe BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 10 0 1 0 0 1
1. Abramson 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,. 5 8 0 1 0 0 1
maraleucel for maraleucel m ma mar mara BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 - 1 9 0 1 0 0 1
lymphomas (TRANSCEND lymphomas l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 (): 3 7 0 1 0 0 1
design study. design d de des desi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ..;():-. 8 6 0 1 0 0 1
2. Bachy 2. 2 2. 2. 2. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,.- 6 10 0 1 0 0 1
of tisagenlecleucel of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 9 0 1 0 0 1
relapsed or relapsed r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 .. 2 9 0 1 0 0 1
2022;28(10):2145-2154. 2022;28(10):2145-2154. 2022;28(10):2145-2154. 2 20 202 2022 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 5 ;():-. 6 3 0 1 0 0 1
3. Bethge 3. 3 3. 3. 3. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,./- 7 9 0 1 0 0 1
outcome analysis outcome o ou out outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 -- 2 8 0 1 0 0 1
lymphoma in lymphoma l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ..;():-. 8 7 0 1 0 0 1
4. Kamdar 4. 4 4. 4. 4. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,. 5 8 0 1 0 0 1
maraleucel versus maraleucel m ma mar mara BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 no 0 8 0 1 0 0 1
followed by followed f fo fol foll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 - 1 8 0 1 0 0 1
line treatment line l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 8 0 1 0 0 1
B-cell lymphoma b-cell B B- B-c B-ce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 -(): 4 7 0 1 0 0 1
analysis of analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 -,,., 5 9 0 1 0 0 1
2022;399(10343):2294-2308. 2022;399(10343):2294-2308. 2022;399(10343):2294-2308. 2 20 202 2022 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 5 ;():-. 6 3 0 1 0 0 1
5. Locke 5. 5 5. 5. 5. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,.- 6 9 0 1 0 0 1
activity of activity a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 - 1 9 0 1 0 0 1
lymphoma (ZUMA-1): lymphoma l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 (-):-,,-. 9 9 0 1 0 0 1
Lancet Oncol. lancet L La Lan Lanc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 .;():-. 7 4 0 1 0 0 1
6. Locke 6. 6 6. 6. 6. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,. 5 8 0 1 0 0 1
ciloleucel as ciloleucel c ci cil cilo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 --. 3 9 0 1 0 0 1
Engl J engl E En Eng Engl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 .;():-. 7 4 0 1 0 0 1
7. Schuster 7. 7 7. 7. 7. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 5 .,,,.- 6 9 0 1 0 0 1
outcomes of outcomes o ou out outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 8 0 1 0 0 1
refractory aggressive refractory r re ref refr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 -():, 5 9 0 1 0 0 1
open-label, single-arm, open-label, o op ope open BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 -,-,.. 6 7 0 1 0 0 1
2021;22(10):1403-1415. 2021;22(10):1403-1415. 2021;22(10):1403-1415. 2 20 202 2021 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 ;():-. 6 3 0 1 0 0 1
8. Berdeja 8. 8 8. 8. 8. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,. 5 8 0 1 0 0 1
autoleucel, a autoleucel, a au aut auto BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 ,-- 3 8 0 1 0 0 1
antigen receptor antigen a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 - 1 8 0 1 0 0 1
refractory multiple refractory r re ref refr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 (-):/ 5 8 0 1 0 0 1
open-label study. open-label o op ope open BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 -..;():-. 9 7 0 1 0 0 1
9. Munshi 9. 9 9. 9. 9. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,.,,. 7 8 0 1 0 0 1
vicleucel in vicleucel v vi vic vicl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 . 1 9 0 1 0 0 1
Med. 2021;384(8):705-716. med. M Me Med Med. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 8 .;():-. 7 3 0 1 0 0 1
10. Cvetkovic 10. 1 10 10. 10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,...;():-; 11 10 0 1 0 0 1
discussion 313-314. discussion d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 -. 2 2 0 1 0 0 1
11. Agency 11. 1 11 11. 11. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .. 2 7 0 1 0 0 1
immunoglobulin for immunoglobulin i im imm immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 ().::// 7 9 0 1 0 0 1
www.ema.europa.eu/en/documents/scientific-guideline/guideline- www.ema.europa.eu/en/documents/scientific-guideline/guideline- www.ema.europa.eu/en/documents/scientific-guideline/guideline- w ww www www. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 ...///-/- 9 8 0 1 0 0 1
core-smpc-human-normal-immunoglobulin-intravenous- core-smpc-human-normal-immunoglobulin-intravenous- core-smpc-human-normal-immunoglobulin-intravenous- c co cor core BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 ------ 6 7 0 1 0 0 1
administration-ivig-rev-5_en.pdf. Accessed administration-ivig-rev-5_en.pdf. a ad adm admi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 ---..,. 7 9 0 1 0 0 1
12. Passweg 12. 1 12 12. 12. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,. 5 9 0 1 0 0 1
transplantation and transplantation t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 . 1 9 0 1 0 0 1
year of year y ye yea year BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 --. 3 8 0 1 0 0 1
activity survey. activity a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 ..;():-. 8 8 0 1 0 0 1
13. Bastos-Oreiro 13. 1 13 13. 13. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .-,,,. 6 9 0 1 0 0 1
option for option o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 - 1 9 0 1 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 8 -:-/ 4 8 0 1 0 0 1
Spanish groups. spanish S Sp Spa Span BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 8 ..;:. 5 6 0 1 0 0 1
14. Kwon 14. 1 14 14. 14. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .,,,. 5 9 0 1 0 0 1
compared to compared c co com comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 8 0 1 0 0 1
B-cell lymphoma. b-cell B B- B-c B-ce BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 8 -..;():-. 9 7 0 1 0 0 1
Haematologica | haematologica H Ha Hae Haem BLOCKSTART PAGESTART SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 no 0 10 0 0 1 0 0
3565 3565 3565 3 35 356 3565 BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 11 0 no 0 10 0 0 0 0 0
ARTICLE -CAR article A AR ART ARTI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 11 0 - 1 10 0 1 0 0 0
O. Penack o. O O. O. O. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 .. 2 6 0 1 0 0 0
15. Alexander 15. 1 15 15. 15. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 9 0 1 0 0 1
T cell t T T T T BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 0 :, 2 8 0 1 0 0 1
toxicity, and toxicity, t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 ,. 2 8 0 1 0 0 1
Transplant Cell transplant T Tr Tra Tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 0 .;():-. 7 6 0 1 0 0 1
16. Hayden 16. 1 16 16. 16. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 9 0 1 0 0 1
children receiving children c ch chi chil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 -: 2 8 0 1 0 0 1
recommendations of recommendations r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 no 0 7 0 1 0 0 1
Marrow Transplantation marrow M Ma Mar Marr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 0 () 2 8 0 1 0 0 1
Committee of committee C Co Com Comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 0 () 2 7 0 1 0 0 1
Haematology Association haematology H Ha Hae Haem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 ().. 4 6 0 1 0 0 1
2022;33(3):259-275. 2022;33(3):259-275. 2022;33(3):259-275. 2 20 202 2022 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 0 ;():-. 6 2 0 1 0 0 1
17. Gazeau 17. 1 17 17. 17. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 10 0 1 0 0 1
anakinra dose anakinra a an ana anak BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 no 0 8 0 1 0 0 1
T-cell therapy. t-cell T T- T-c T-ce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 0 -..;():. 8 6 0 1 0 0 1
18. Jain 18. 1 18 18. 18. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,. 5 9 0 1 0 0 1
patients receiving patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 - 1 9 0 1 0 0 1
hematologic malignancies. hematologic h he hem hema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 0 ..;():-. 8 8 0 1 0 0 1
19. Rejeski 19. 1 19 19. 19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,,.-: 7 9 0 1 0 0 1
for CAR for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 --/ 3 9 0 1 0 0 1
large B-cell large l la lar larg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 0 -..;():-. 9 7 0 1 0 0 1
20. Sharma 20. 2 20 20. 20. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 0 .,,.- 5 9 0 1 0 0 1
therapy -A therapy t th the ther BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 0 -. 2 6 0 1 0 0 1
Cancers (Basel). cancers C Ca Can Canc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 6 ().;():. 8 4 0 1 0 0 1
21. Penack 21. 2 21 21. 21. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 8 0 1 0 0 1
after CD19 after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -: 2 8 0 1 0 0 1
EBMT Transplant ebmt E EB EBM EBMT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 . 1 8 0 1 0 0 1
Cancer. 2023;11(4):e006406. cancer. C Ca Can Canc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 6 .;():. 6 3 0 1 0 0 1
22. Gagelmann 22. 2 22 22. 22. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
boost for boost b bo boo boos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -: 2 8 0 1 0 0 1
GLA/DRST study. gla/drst G GL GLA GLA/ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 /..;():-. 9 6 0 1 0 0 1
23. Rejeski 23. 2 23 23. 23. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 10 0 1 0 0 1
stem cell stem s st ste stem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 no 0 8 0 1 0 0 1
after CD19 after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -..;():-. 9 8 0 1 0 0 1
24. Bethge 24. 2 24 24. 24. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,./- 7 8 0 1 0 0 1
outcome analysis outcome o ou out outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 -- 2 8 0 1 0 0 1
lymphoma in lymphoma l ly lym lymp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 ..;():-. 8 6 0 1 0 0 1
25. Dreger 25. 2 25 25. 25. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
of CAR-T of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 --:/ 4 8 0 1 0 0 1
experience. Bone experience. e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;():-. 8 7 0 1 0 0 1
26. Greco 26. 2 26 26. 26. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,. 5 9 0 1 0 0 1
therapies for therapies t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 :- 2 7 0 1 0 0 1
statement and statement s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 no 0 7 0 1 0 0 1
EBMT practice ebmt E EB EBM EBMT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 . 1 7 0 1 0 0 1
EClinicalMedicine. 2024;69:102476. eclinicalmedicine. E EC ECl ECli BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 6 .;:. 4 4 0 1 0 0 1

